10月30日,生物科技公司君实生物(01877.HK,688180.SH)盘中股价大跌5.07%,引发市场关注。
此前,君实生物公布了2024年前三季度业绩。业绩报告显示,君实生物前三季度实现营收12.71亿元,同比增长28.87%;归属母公司净亏损9.27亿元,同比减亏34.12%。核心产品特瑞普利单抗的销售在国内大肿瘤适应症获批后继续放量,带动公司收入大幅增长,亏损收窄。
但与此同时,君实生物5%以上股东上海檀英及其一致行动人却在近期频繁减持公司股份。数据显示,上海檀英及一致行动人自8月24日以来合计减持公司股份逾1000万股,持股比例从10.7876%降至9.73%,降幅超过1%。大股东频繁减持引发市场对公司长期前景的担忧。
分析人士指出,虽然君实生物最新业绩显示其主力产品销售情况向好,但大股东频繁减持或表明其对公司中长期前景缺乏信心。短期内公司股价或将继续承压。不过长远来看,君实生物的业务发展仍需进一步观察。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.